Bessent to Senate: Pass CLARITY Act or Forfeit Crypto Security Tools on Sept. 15
Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock By Investing.com
- Investing
Ramit Sethi- 3 minutes read
Metagenomi Therapeutics () Chief Financial Officer Pamela Wapnick disposed of common stock valued at $2,213 on September 8, 2026.
The transaction involved the sale of 1,911 shares at a price of $1.1584 per share. This disposition was not a volitional trade by Ms. Wapnick but an automatic sale to satisfy tax withholding obligations. These obligations arose from the vesting of restricted stock units granted to Ms. Wapnick on April 1, 2024, and April 1, 2025.
Following this transaction, Ms. Wapnick directly holds 206,580 shares of Metagenomi Therapeutics common stock.The stock is currently trading at $1.17, hovering just above its 52-week low of $1.13, reflecting a challenging year with shares down 37.5% over the past twelve months. The company’s market capitalization stands at $43.44 million. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts maintaining price targets between $5 and $9. The platform offers 11 additional ProTips for MGX investors seeking deeper insights into the company’s prospects.
In other recent news, Metagenomi Inc reported its second-quarter 2026 financial results, revealing a net loss per share of $0.73. This result fell short of the consensus estimate, which anticipated a loss of $0.55 per share. The larger-than-expected loss was attributed to a $2.6 million non-cash Ionis collaboration adjustment and increased research and development expenses. Wells Fargo responded by lowering its price target for Metagenomi shares from $9.00 to $7.00, although it maintained an Overweight rating on the stock.
Additionally, Chardan initiated coverage of Metagenomi with a buy rating and set a price target of $5.00. This evaluation is based on the potential of Metagenomi’s lead asset, MGX-001, as a one-time treatment for Hemophilia A. Analyst Keay Nakae has taken over coverage for the company at Chardan, maintaining the buy rating. These developments highlight the ongoing interest and varied perspectives on Metagenomi’s financial performance and product potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
